Advanced Enzyme Tech Quarterly Results for Trading Insights
In Mar 2026, Advanced Enzyme Tech (ADVENZYMES) reported revenue ₹211 Cr and net profit ₹45 Cr — revenue +19.9% YoY. For annual financials, live price and key ratios, visit Advanced Enzyme Tech share price chart.
ADVENZYMES Quarterly Results — Revenue, Profit & EPS Highlights
Advanced Enzyme Tech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Advanced Enzyme Tech share price performance to track price trends across different timeframes.
- Revenue of ₹211 Cr in Mar 2026 (+3.9% vs Jun 2026, +19.9% vs Mar 2025)
- Net Profit of ₹45 Cr in Mar 2026 (+15.4% vs Jun 2026, +66.7% vs Mar 2025)
- EBITDA of ₹71 Cr in Mar 2026 (+10.9% vs Jun 2026)
- Operating Margin of 31.0% in Mar 2026 (+4.0pp vs Jun 2026)
- Earnings Per Share of ₹3.84 in Mar 2026 (+16.0% vs Jun 2026)
Advanced Enzyme Tech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ADVENZYMES quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 211 | 203 | 195 | 176 | 195 | 3.9% | 19.9% |
| Net Profit (₹ Cr) | 45 | 39 | 45 | 27 | 40 | - | - |
| EBITDA (₹ Cr) | 71 | 64 | 70 | 54 | 65 | - | - |
| EPS (₹) | 3.84 | 3.31 | 3.87 | 2.37 | 3.57 | - | - |
| Operating Margin (%) | 31.0% | 27.0% | 33.0% | 27.0% | 30.0% | - | - |
ADVENZYMES Share Price Trend — 1-Year Movement Across Quarterly Results
Advanced Enzyme Tech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse ADVENZYMES cash flow statement for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ADVENZYMES vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Advanced Enzyme Tech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1900.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.1 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8560.0 | 2,986 | 751 | -5.0% | - | 25.2% | 302.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 5013.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 435.5 |
|
Cipla
Mar 2026 |
₹114,875.60 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1104.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 87.3 |
All amounts in ₹ Crores